Comparison of disease response between the decitabine combined with cedazuridine and intravenous decitabine was not possible because all participants received decitabine combined with cedazuridine starting from Cycle 3.The FDA approval of decitabine combined with cedazuridine was based on clinical trial results which showed similar drug concentrations between intravenous decitabine and decitabine combined with cedazuridine. Additionally, about half of the participants who were formerly dependent on transfusions were able to no longer require transfusions during an 8-week period. The safety profile of decitabine combined with cedazuridine was also similar to intravenous decitabine. The FDA granted the approval of Inqovi to Astex Pharmaceuticals, Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd.

References
External links
"Decitabine". Drug Information Portal. U.S. National Library of Medicine. "Cedazuridine". Drug Information Portal. U.S. National Library of Medicine. "Decitabine". National Cancer Institute. "Cedazuridine". National Cancer Institute. Clinical trial number NCT02103478 for "Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS" at ClinicalTrials.gov
Clinical trial number NCT03306264 for "Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML" at ClinicalTrials.gov
"ASTX727 – Hematologic Malignancies". Astex.
Estramustine (INN, USAN, BAN) is an estrogen and cytostatic antineoplastic agent which was never marketed. It is an estrogen ester – specifically, the C3 normustine ester of estradiol – and acts in part as a prodrug of estradiol in the body. Estramustine phosphate, the C17β phosphate ester of estramustine and a prodrug of estramustine, estromustine, estradiol, and estrone, is marketed and used in the treatment of prostate cancer. See also
List of hormonal cytostatic antineoplastic agents
List of estrogen esters § Estradiol esters


== References ==